GlassScriptPhysician profile
Joseph M Wang
NPI 1578564613
$2,768.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $388 · 2021: $252 · 2022: $815 · 2023: $397 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.12 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $727.18 | 2020-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $638.58 | 2019-2023 | |
| Astellas Pharma US INC | $370.78 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $195.77 | 2019-2020 | |
| Seagen INC. | $147.90 | 2021-2022 | |
| Stemline Therapeutics INC. | $124.28 | 2024 | Orserdu |
| Ferring Pharmaceuticals INC. | $118.62 | 2019-2022 | |
| Amgen INC. | $110.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $106.91 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $104.62 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.03 | 2019 | |
| Dendreon Pharmaceuticals LLC | $26.40 | 2019 | |
| Reflexion Medical, INC. | $22.24 | 2023 | Reflexion Medical Radiotherapy System |
| Novartis Pharmaceuticals Corporation | $18.27 | 2021 | |
| Abbvie INC. | $16.40 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.